Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ATM Kinase Inhibitor AZD1390

Phase 1Small molecule

CChildren's Oncology Group

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChildhoodActive, not recruiting

ChildhoodPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Childhood

NCT06894979

Clinical

Trials by Indication[1]

Childhood1 trial

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD1390 (NSC# 852149) When Combined With Focal Radiation in Pediatric Patients With High Grade Glioma

Active, not recruiting·CChildren's Oncology Group·Phase 1·NCT06894979·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ATM Kinase Inhibitor AZD1390. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATM Kinase Inhibitor AZD1390 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATM Kinase Inhibitor AZD1390. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CChildren's Oncology Group

Related News